Difubenzuron

CAS No. 35367-38-5

Difubenzuron( Diflubenzuron | DU 112307 | DU112307 | DU-112307 )

Catalog No. M18469 CAS No. 35367-38-5

Diflubenzuron is a benzoyl-urea insecticide, found to be a potent inhibitor of melanosome synthesis in mouse melanoma cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 50 In Stock
100MG 188 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Difubenzuron
  • Note
    Research use only, not for human use.
  • Brief Description
    Diflubenzuron is a benzoyl-urea insecticide, found to be a potent inhibitor of melanosome synthesis in mouse melanoma cells.
  • Description
    Diflubenzuron is an insect growth regulator and chitin synthesis inhibitor. It inhibits growth of Tribolium, Anopheles, Ascaris and Haemonchus.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Diflubenzuron | DU 112307 | DU112307 | DU-112307
  • Pathway
    Endocrinology/Hormones
  • Target
    Reductase
  • Recptor
    CYP1A1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    35367-38-5
  • Formula Weight
    310.68
  • Molecular Formula
    C14H9ClF2N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Fc1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1
  • Chemical Name
    N-((4-chlorophenyl)carbamoyl)-2,6-difluorobenzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Norman J O, Meola S M. Inhibition of melanogenesis in B16-F1 melanoma cells after exposure to diflubenzuron.[J]. Antimicrobial Agents & Chemotherapy, 1983, 23(2):313-6.
molnova catalog
related products
  • Turosteride

    Turosteride is a small molecule steroidal 5α-reductase (5α-reductase) inhibitor.

  • BYAKANGELICIN(b)

    BYAKANGELICINa main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitorand is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.

  • AT-007

    AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM).